TickerKhojHospitals & Diagnostics · Medical/Nursing Services · NSE: THYROCARE · data 2026-11-02
Thyrocare Technologies Ltd
In plain words
Price: 31.4% below its 52-week high of ₹662.
Delivery: 47.1% of traded shares were kept for delivery over the last 10 sessions, against 53.3% over the last 60.
Latest results: a net profit of ₹16 cr for the quarter ended Sept 2026 (-66.9% on the same quarter a year earlier).
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹930 cr |
| Net profit (last 12 months) | ₹144 cr |
| Sales growth, 3 years (yearly) | 16.3% |
| Profit growth, 3 years (yearly) | 36.2% |
At a glance
Promoters 51.0% (-20.0 pts in a year), pledged 0.0%, institutions 35.3%.
P/E 50.8, P/B 13.1, dividend yield 2.0%. Price relative to earnings and book value (low is cheaper, not better).
ROE 28.8%, ROCE 34.2%, operating margin 25.6%: how much profit it earns on the money it uses.
Debt/equity 0.09, Profit growth 36.2% and sales growth 16.3% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
- Virtually debt-free (debt/equity 0.1 or less).
- High return on equity (28.8%).
- Healthy operating margin (25.6%).
- Profit grew 36.2% a year over 3 years.
- Pays a dividend yielding 2.0%.
- Promoters cut their holding by 20.0 points in a year.
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Latest results in brief (Q2 FY27)
THYROCARE Q2 FY27 results (consolidated figures, as filed on NSE).
Revenue was ₹270.81 crore, up 25.1% YoY and up 12.8% QoQ.
Net profit was ₹15.89 crore, down 66.9% YoY and down 69.6% QoQ.
Operating margin was 33% (33% a year ago).
EPS was ₹0.96, down 66.9% YoY and down 70.3% QoQ.
THYROCARE के Q2 FY27 नतीजे (कंसोलिडेटेड आंकड़े, NSE पर दाखिल)।
राजस्व: ₹270.81 करोड़; पिछले साल की तुलना में 25.1% की बढ़त, पिछली तिमाही की तुलना में 12.8% की बढ़त।
शुद्ध मुनाफ़ा: ₹15.89 करोड़; पिछले साल की तुलना में 66.9% की गिरावट, पिछली तिमाही की तुलना में 69.6% की गिरावट।
ऑपरेटिंग मार्जिन: 33% (एक साल पहले 33%)।
EPS: ₹0.96; पिछले साल की तुलना में 66.9% की गिरावट, पिछली तिमाही की तुलना में 70.3% की गिरावट।
THYROCAREના Q2 FY27 પરિણામો (કન્સોલિડેટેડ આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹270.81 કરોડ; ગયા વર્ષની સરખામણીએ 25.1% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 12.8% વધારો.
ચોખ્ખો નફો: ₹15.89 કરોડ; ગયા વર્ષની સરખામણીએ 66.9% ઘટાડો, ગયા ક્વાર્ટરની સરખામણીએ 69.6% ઘટાડો.
ઓપરેટિંગ માર્જિન: 33% (એક વર્ષ પહેલાં 33%).
EPS: ₹0.96; ગયા વર્ષની સરખામણીએ 66.9% ઘટાડો, ગયા ક્વાર્ટરની સરખામણીએ 70.3% ઘટાડો.
Written from the filed numbers. Not a recommendation.
Smart-money activity
33/100 · Neutral over the last ~60 sessions, data 2026-11-02
- Delivery vs usual 12/30: Delivery 47.0% over the last 20 sessions vs 50.7% in the 40 before (0.93x); shares delivered per day 1.32x usual; 2 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 9/15: 0 insider buy days (promoter group among them) and 2 SAST acquisition days in 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 7/15: 5 schemes hold it, about ₹492 cr in all (as of 2026-09-30). Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Results ● Insider ● Dividend ● Bonus
- 29 Oct 26Results Q2 FY27 results: profit −66.9% YoY -7.7% next session
- 21 Sept 26Insider SAST disclosure: API Holdings Ltd acquired 8,12,00,000 shares +3.9% next session
- 17 Aug 26Insider SAST disclosure: Docon Technologies Private Limited +3 acquired 9,99,69,427 shares -2.5% next session
- 23 Jul 26Results Q1 FY27 results: profit +34.1% YoY +1.1% next session
- 23 Jun 26Dividend Dividend ₹7 (ex-date) +2.0% next session
- 7 May 26Results Q4 FY26 results: profit +117.1% YoY +5.2% next session
- 28 Jan 26Results Q3 FY26 results: profit +51.8% YoY -6.4% next session
- 28 Nov 25Bonus Bonus 2:1 (ex-date)
- 24 Oct 25Dividend Dividend ₹7 (ex-date) +3.0% next session
- 14 Oct 25Results Q2 FY26 results: profit +1.3% YoY -1.8% next session
- 25 Jul 25Dividend Dividend ₹21 (ex-date) -6.8% next session
- 23 Jul 25Results Q1 FY26 results: profit +61.1% YoY +12.6% next session
- 24 Apr 25Results Q4 FY25 results: profit +22.0% YoY +17.3% next session
- 25 Feb 25Results Q3 FY25 results: profit +24.5% YoY +1.3% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Sept 2026 | ₹271 cr | ₹16 cr | -66.9% | 33.0% | 0.96 |
| Jun 2026 | ₹240 cr | ₹52 cr | +34.1% | 32.2% | 3.23 |
| Mar 2026 | ₹224 cr | ₹47 cr | +117.1% | 33.5% | 2.99 |
| Dec 2025 | ₹196 cr | ₹29 cr | +51.8% | 29.6% | 1.82 |
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 51.02% | 60.92% | 60.92% | 60.93% |
| Foreign institutions (FII) | 9.37% | 5.44% | 5.37% | 4.95% |
| Domestic institutions (DII) | 25.92% | 20.92% | 20.99% | 20.51% |
| Mutual funds | 22.91% | 19.86% | 19.45% | 18.60% |
| Retail investors | 8.97% | 8.57% | 8.54% | 8.92% |
| Number of shareholders | 75,186 | 73,064 | 73,377 | 77,619 |
Common questions
What was Thyrocare Technologies Ltd's latest quarterly profit?
Thyrocare Technologies Ltd reported a net profit of ₹16 cr for the quarter ended Sept 2026 (-66.9% on the same quarter a year earlier), on revenue of ₹271 cr.
How much do promoters hold in Thyrocare Technologies Ltd?
Promoters held 51.02% of Thyrocare Technologies Ltd at the end of Sept 2026, with 0.00% of promoter shares pledged.
Is Thyrocare Technologies Ltd debt-free?
Its latest reported debt-to-equity ratio is 0.09, which is very low.
What is Thyrocare Technologies Ltd's P/E ratio?
About 50.8, based on the last 12 months' earnings and a price of ₹454.35 (data 2026-11-02).
What is the 52-week high and low of Thyrocare Technologies Ltd?
The 52-week high is ₹662 and the 52-week low is ₹342.55.
Mutual funds holding Thyrocare Technologies Ltd
From the monthly portfolios of the fund houses the site reads, as of 2026-09-30. 5 schemes holding about ₹492 cr; funds that hold it outside their top holdings may not be listed.
| Scheme | Fund house | % of fund | Value |
|---|---|---|---|
| ADITYA BIRLA SUN LIFE ELSS TAX SAVER FUND | Aditya Birla Sun Life Mutual Fund | 1.58% | ₹214 cr |
| NIPPON INDIA PHARMA FUND | Nippon India Mutual Fund | 2.24% | ₹205 cr |
| ADITYA BIRLA SUN LIFE BUSINESS CYCLE FUND | Aditya Birla Sun Life Mutual Fund | 2.18% | ₹38 cr |
| ADITYA BIRLA SUN LIFE PHARMA & HEALTHCARE FUND | Aditya Birla Sun Life Mutual Fund | 1.76% | ₹19 cr |
| An open ended fund for investment for children having a lock-in for at least 5 years or till the child attains age of majority | Aditya Birla Sun Life Mutual Fund | 1.34% | ₹16 cr |
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Thyrocare Technologies Ltd | ₹454.35 | ₹7,274 cr | 50.8 | 13.1 | 28.8% | 34.2% | 0.09 | +0.8% |
| Dr. Agarwal's Health Care Ltd. | ₹513.2 | ₹16,116 cr | 110.4 | — | 6.8% | 9.1% | 0.53 | -2.2% |
| Vijaya Diagnostic Centre Ltd. | ₹1,450.1 | ₹14,906 cr | 79.7 | — | 19.7% | 19.6% | 0.44 | +45.6% |
| Metropolis Healthcare Ltd. | ₹551.75 | ₹11,309 cr | 56.8 | — | 13.4% | 16.3% | 0.15 | +12.4% |
| Nephrocare Health Services Limited | ₹611.4 | ₹6,194 cr | — | — | 9% | 14.6% | 0.07 | +24.8% |
| Jeena Sikho Lifecare Limited | ₹341.25 | ₹4,149 cr | 18 | — | 60% | 62.7% | 0.27 | -54.4% |
Compare THYROCARE with AGARWALEYE in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open THYROCARE in TickerKhoj →